Log In
BCIQ
Print this Print this
 

Narcan, naloxone

Also known as: Narcan Nasal Spray

  Manage Alerts
Collapse Summary General Information
Company Opiant Pharmaceuticals Inc.
DescriptionOpioid antagonist nasal spray
Molecular Target
Mechanism of ActionOpioid receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationAddiction
Indication DetailsReverse opioid overdose; Treat and prevent binge eating disorder; Treat binge eating disorder; Treat binge eating disorder in overweight and obese patients; Treat bulimia nervosa; Treat opioid addiction; Treat overeating in patients with premenstrual syndrome (PMS)
Regulatory Designation U.S. - Fast Track (Reverse opioid overdose)
PartnerAdapt Pharma Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$56.0M

$1.0M

$55.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today